PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation
Conclusion:
Colorectal cancer is a clinically and molecularly heterogenic disease which requires comprehensive genetic testing to screen for r are genetic alterations like POLE mutations to detect tumors harboring an ultramutator phenotype especially in patients that are refractory to standard chemotherapy.
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Brain | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Genetics | Immunotherapy | Neurology | Study